“In late December, we expect the FDA's decision on the subcutaneous formulation of nivolumab.”

In context

“l for long-term growth and returns. We remain focused on our near-term goal of delevering our balance sheet. We made further progress during Q3 and are on track to pay down our target of $10 billion of debt by the first half of 2026. We're committed to the dividend, and we will continue to invest strategically in growth through our own pipeline as well as sourcing innovation externally. Now turning to upcoming milestones on Slide 7. At the American College of Rheumatology's Annual Meeting in November, we will present promising Phase 1 data for our CD19 NEX-T cell therapy. This is a next-generation immunology asset, leveraging the Breyanzi construct. We are optimistic about its potential to deliver benefits for patients across multiple immunology indications by resetting the immune system. In late December, we expect the FDA's decision on the subcutaneous formulation of nivolumab. We anticipate this launch in early 2025 will provide an important benefit for both patients and physicians while extending our leadership in immuno-oncology into the next decade. We're also on track to share top-line Phase 3 data from Sotyktu in psoriatic arthritis by year-end. This data should help strengthen the competitive profile for Sotyktu as roughly 1/3 of psoriasis patients also have psoriatic arthritis. Turning to our outlook on Slide 8. Given the strength of our results year-to-date, we are raising both our full year revenue target and our full year EPS guidance. David will discuss these updates in more detail shortly. Looking ahead, I'm confident in our ability to deliver long-term value for patients and our shareholders. To summarize on Slide 9, I'm pleased with our achievemen”